Epidemiology, Ventilation Management and Outcomes of COVID-19 ARDS Patients Versus Patients with ARDS Due to Pneumonia in the Pre-COVID Era
Overview
Authors
Affiliations
Background: Ventilation management may differ between COVID-19 ARDS (COVID-ARDS) patients and patients with pre-COVID ARDS (CLASSIC-ARDS); it is uncertain whether associations of ventilation management with outcomes for CLASSIC-ARDS also exist in COVID-ARDS.
Methods: Individual patient data analysis of COVID-ARDS and CLASSIC-ARDS patients in six observational studies of ventilation, four in the COVID-19 pandemic and two pre-pandemic. Descriptive statistics were used to compare epidemiology and ventilation characteristics. The primary endpoint were key ventilation parameters; other outcomes included mortality and ventilator-free days and alive (VFD-60) at day 60.
Results: This analysis included 6702 COVID-ARDS patients and 1415 CLASSIC-ARDS patients. COVID-ARDS patients received lower median V (6.6 [6.0 to 7.4] vs 7.3 [6.4 to 8.5] ml/kg PBW; p < 0.001) and higher median PEEP (12.0 [10.0 to 14.0] vs 8.0 [6.0 to 10.0] cm HO; p < 0.001), at lower median ΔP (13.0 [10.0 to 15.0] vs 16.0 [IQR 12.0 to 20.0] cm HO; p < 0.001) and higher median Crs (33.5 [26.6 to 42.1] vs 28.1 [21.6 to 38.4] mL/cm HO; p < 0.001). Following multivariable adjustment, higher ΔP had an independent association with higher 60-day mortality and less VFD-60 in both groups. Higher PEEP had an association with less VFD-60, but only in COVID-ARDS patients.
Conclusions: Our findings show important differences in key ventilation parameters and associations thereof with outcomes between COVID-ARDS and CLASSIC-ARDS.
Trial Registration: Clinicaltrials.gov (identifier NCT05650957), December 14, 2022.
Anwar S, Alhumaydhi F, Rahmani A, Kumar V, Alrumaihi F Diseases. 2024; 12(12.
PMID: 39727640 PMC: 11726889. DOI: 10.3390/diseases12120310.
An Overview of Pediatric Pulmonary Complications During COVID-19 Pandemic: A Lesson for Future.
Roshanzamir Z, Mohammadi F, Yadegar A, Naeini A, Hojabri K, Shirzadi R Immun Inflamm Dis. 2024; 12(11):e70049.
PMID: 39508631 PMC: 11542302. DOI: 10.1002/iid3.70049.